ProteoTech Inc., is a private drug development Company founded in 1996 that is located in the Seattle, WA area (Kirkland, WA), and is focused on targeting misfolded proteins and amyloid diseases. ProteoTech is utilizing its amyloid and proteoglycan expertise in an effort to transform the lives of victims of Alzheimer's disease, Parkinson's disease, type 2 diabetes and systemic amyloid disease (including AL, TTR and AA amyloidosis).

With over 225 patents in its intellectual property estate, ProteoTech is in human clinical trials for its orally active small molecule drug Exebryl-1^® for the treatment of mild-to-moderate Alzheimer's disease, and an orally active small molecule drug, Systebryl™, for the treatment of AL (immunoglobulin light chain) amyloidosis.

The Company is in late stage pre-clinical development with Synuclere™ for the treatment of Parkinson's disease, and is also in late stage pre-clinical development for a novel small peptide called PeptiClere™ for the treatment of Alzheimer's disease. ProteoTech is additionally developing a novel small molecule compound for the treatment of amyloidosis associated with type 2 diabetes.

Alzheimers Target:Beta-amyloid Protein	Parkinson's Target:Alpha-synuclein
Human Alzheimer's brain filled with amyloid plaques (arrows) (click image to enlarge)	Neuron in the substantia nigra with a Lewy body containing alpha-synuclein (click image to enlarge)
AL Amyloidosis Target:AL Amyloid Protein	Type 2 Diabetes Target:Islet Amyloid Polypeptide
AL Amyloid in heart (click image to enlarge)	Congo red staining of IAPP amyloid deposits in Islet of Langerhans (pancreas) of patient with Type 2 Diabetes (click image to enlarge)